Literature DB >> 30986029

Codelivery of Plasmid and Curcumin with Mesoporous Silica Nanoparticles for Promoting Neurite Outgrowth.

Cheng-Shun Cheng1, Tsang-Pai Liu2,3, Fan-Ching Chien4, Chung-Yuan Mou1, Si-Han Wu, Yi-Ping Chen.   

Abstract

Reactive oxygen species (ROS)-induced oxidative stress leads to neuron damage and is involved in the pathogenesis of chronic inflammation in neurodegenerative diseases (NDs), such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis. Researchers, therefore, are looking for antiinflammatory drugs and gene therapy approaches to slow down or even prevent neurological disorders. Combining therapeutics has shown a synergistic effect in the treatment of human diseases. Many nanocarriers could be designed for the simultaneous codelivery of drugs with genes to fight diseases. However, only a few researches have been performed in NDs. In this study, we developed a mesoporous silica nanoparticle (MSN)-based approach for neurodegenerative therapy. This MSN-based platform involved multiple designs in the targeted codelivery of (1) curcumin, a natural antioxidant product, to protect ROS-induced cell damage and (2) plasmid RhoG-DsRed, which is associated with the formation of lamellipodia and filopodia for promoting neurite outgrowth. At the same time, TAT peptide was introduced to the plasmid RhoG-DsRed via electrostatic interaction to elevate the efficiency of nonendocytic pathways and the nuclear plasmid delivery of RhoG-DsRed in cells for enhanced gene expression. Besides, such a plasmid RhoG-DsRed/TAT complex could work as a noncovalent gatekeeper. The release of curcumin inside the channel of the MSN could be triggered when the complex was dissociated from the MSN surface. Taken together, this MSN-based platform combining genetic and pharmacological manipulations of an actin cytoskeleton as well as oxidative stress provides an attractive way for ND therapy.

Entities:  

Keywords:  codelivery; combining therapy; mesoporous silica nanoparticles; neurite growth; neurodegenerative diseases

Mesh:

Substances:

Year:  2019        PMID: 30986029     DOI: 10.1021/acsami.9b02797

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  5 in total

Review 1.  Delivering the Promise of Gene Therapy with Nanomedicines in Treating Central Nervous System Diseases.

Authors:  Meihua Luo; Leo Kit Cheung Lee; Bo Peng; Chung Hang Jonathan Choi; Wing Yin Tong; Nicolas H Voelcker
Journal:  Adv Sci (Weinh)       Date:  2022-07-18       Impact factor: 17.521

Review 2.  Recent Advances in the Treatment of Alzheimer's Disease Using Nanoparticle-Based Drug Delivery Systems.

Authors:  Prashant Poudel; Soyeun Park
Journal:  Pharmaceutics       Date:  2022-04-11       Impact factor: 6.525

Review 3.  Combination of cell-penetrating peptides with nanomaterials for the potential therapeutics of central nervous system disorders: a review.

Authors:  Ying Zhang; Pan Guo; Zhe Ma; Peng Lu; Dereje Kebebe; Zhidong Liu
Journal:  J Nanobiotechnology       Date:  2021-08-23       Impact factor: 10.435

4.  Modeling the Properties of Curcumin Derivatives in Relation to the Architecture of the Siloxane Host Matrices.

Authors:  Florentina Monica Raduly; Valentin Rădiţoiu; Alina Rădiţoiu; Adriana Nicoleta Frone; Cristian Andi Nicolae; Violeta Purcar; Georgiana Ispas; Mariana Constantin; Iuliana Răut
Journal:  Materials (Basel)       Date:  2021-12-30       Impact factor: 3.623

5.  Bridging Size and Charge Effects of Mesoporous Silica Nanoparticles for Crossing the Blood-Brain Barrier.

Authors:  Yi-Ping Chen; Chih-Ming Chou; Tsu-Yuan Chang; Hao Ting; Julien Dembélé; You-Tai Chu; Tsang-Pai Liu; Chun A Changou; Chien-Wei Liu; Chien-Tsu Chen
Journal:  Front Chem       Date:  2022-06-27       Impact factor: 5.545

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.